

Press Release

Steffen Saltofte (Zentiva) named President of Medicines for Europe

Brussels, 07 January 2026

Steffen Saltofte, CEO of Zentiva, has been appointed as President of Medicines for Europe for the period 2026-2028. The change follows Markus Sieger's retirement from the Presidency of the association.

With a strong vision for the future of the off-patent medicines sector, Steffen intends to focus on:

- Protecting access and affordability for patients
- Pharmaceutical resilience and competitiveness
- Ensuring a modern, harmonised, and simple regulatory framework that enables the off-patent industry to deliver
- Balancing sustainability with our access responsibility.

Beginning his term as President, Steffen Saltofte said: *"I am very excited to begin my mandate as Medicines for Europe President. I thank the members who have put their trust in me. I will focus on partnerships to build policies to safeguard patient access in the years to come as our industry faces new challenges and geopolitical shifts that have a real impact on our sector. As its President, I am ready to support Medicines for Europe in building health security, improving open strategic autonomy, delivering equitable access for patients, and taking meaningful steps towards sustainable production."*

Elisabeth Stampa (Medichem), Christoph Delenta (Sandoz) and Marc Crouton (Fresenius Kabi) will be Vice-Presidents of the association. Theodore Tryfon (Elpen) will be Vice-President during the Greek Presidency of the Council of the EU.

About Steffen Saltofte, CEO of Zentiva, President at Medicines for Europe



Steffen Saltofte
Chief Executive Officer, Zentiva Group

Steffen Saltofte has been CEO of the Zentiva Group since 2023, leading a team of more than 5,000 colleagues across 30 countries, all united by a shared mission to make high-quality, affordable medicines accessible to people across Europe.

Before joining Zentiva, Steffen was CEO of pharmaceutical company, Acino, and prior to this, held senior roles at Boehringer Ingelheim, Merial, Syngenta, and Maersk Line.

Steffen holds an MBA from IMD and bachelor's degrees from Copenhagen Business School and the Institute of Chartered Shipbrokers. Fluent in Danish and English, with proficiency in Swedish and German, Steffen brings a global perspective to his leadership.

Steffen is taking on the Presidency of Medicines for Europe from January 2026, having been a Vice President since 2025.

Medicines for Europe Vice Presidents

L-R: Marc Crouton (Fresenius Kabi), Steffen Saltofte (Zentiva), Elisabeth Stampa (Medichem), Christoph Delenta (Sandoz)



Medicines for Europe Executive committee 2026/2028

L-R: Michele Uda (Egualia), Jean Hermans (Bogin), Martha Christopoulou (Baxter), Lucas Sigman (Insud), Artur Cwiok (Viatris), Markus Sieger (departing member), Philippe Dreschle (departing member), Elisabeth Stampa (Medichem), Michal Nitka (Teva), Marc Crouton (Fresenius Kabi), Christophe Delenta (Sandoz), Adrian van den Hoven (Medicines for Europe), Steffen Saltofte (Zentiva), Christos Gallis (Stada), Bork Bretthauer (ProGenerika).

Not pictured: Theodore Tryfon (Elpen), Paul Tredwell (Accord), Anish Mehta (Synthon), Giuliana Pennisi (Medicines for Europe).



Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in Research and Development. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information, please follow us at www.medicinesforeurope.com and on LinkedIn and X @medicinesforEU.